Schwab Charles Investment Management Inc. Grows Stake in Alnylam Pharmaceuticals, Inc. (ALNY)

Schwab Charles Investment Management Inc. grew its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 0.5% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 244,550 shares of the biopharmaceutical company’s stock after buying an additional 1,135 shares during the period. Schwab Charles Investment Management Inc. owned 0.26% of Alnylam Pharmaceuticals worth $28,733,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Fayerweather Charles acquired a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at $230,000. Watch Point Trust Co acquired a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at $235,000. QS Investors LLC increased its stake in shares of Alnylam Pharmaceuticals by 59.7% in the 2nd quarter. QS Investors LLC now owns 2,408 shares of the biopharmaceutical company’s stock valued at $192,000 after buying an additional 900 shares during the period. The Manufacturers Life Insurance Company increased its stake in shares of Alnylam Pharmaceuticals by 7.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,541 shares of the biopharmaceutical company’s stock valued at $203,000 after buying an additional 167 shares during the period. Finally, CIBC Asset Management Inc acquired a new stake in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at $221,000. 88.43% of the stock is owned by institutional investors.

Alnylam Pharmaceuticals, Inc. (NASDAQ ALNY) opened at $128.20 on Tuesday. The company has a debt-to-equity ratio of 0.14, a current ratio of 9.83 and a quick ratio of 9.83. Alnylam Pharmaceuticals, Inc. has a twelve month low of $35.98 and a twelve month high of $147.63.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.23) by ($0.11). The business had revenue of $17.10 million for the quarter, compared to the consensus estimate of $28.15 million. Alnylam Pharmaceuticals had a negative return on equity of 46.94% and a negative net margin of 664.70%. The business’s revenue was up 24.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($1.21) earnings per share. sell-side analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -5.21 earnings per share for the current year.

Several equities research analysts have recently commented on ALNY shares. Needham & Company LLC reissued a “buy” rating and issued a $85.00 target price (down from $98.00) on shares of Alnylam Pharmaceuticals in a research note on Thursday, September 7th. BMO Capital Markets restated an “outperform” rating and issued a $99.00 price target (down from $105.00) on shares of Alnylam Pharmaceuticals in a research report on Wednesday, September 6th. Instinet initiated coverage on Alnylam Pharmaceuticals in a research report on Friday, September 15th. They issued a “reduce” rating and a $56.00 price target on the stock. Piper Jaffray Companies restated an “overweight” rating and issued a $110.00 price target (down from $126.00) on shares of Alnylam Pharmaceuticals in a research report on Thursday, September 7th. Finally, Leerink Swann restated a “market perform” rating and issued a $72.00 price target (down from $83.00) on shares of Alnylam Pharmaceuticals in a research report on Friday, September 8th. They noted that the move was a valuation call. Three investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and sixteen have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $121.85.

In other Alnylam Pharmaceuticals news, SVP Laurie Keating sold 30,000 shares of Alnylam Pharmaceuticals stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $135.89, for a total transaction of $4,076,700.00. Following the transaction, the senior vice president now directly owns 41,500 shares in the company, valued at $5,639,435. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO John Maraganore sold 74,000 shares of Alnylam Pharmaceuticals stock in a transaction dated Wednesday, November 15th. The stock was sold at an average price of $126.86, for a total value of $9,387,640.00. Following the transaction, the chief executive officer now owns 223,710 shares in the company, valued at $28,379,850.60. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 393,212 shares of company stock worth $48,109,436. Corporate insiders own 4.30% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was reported by Week Herald and is the property of of Week Herald. If you are reading this report on another website, it was illegally stolen and republished in violation of U.S. & international copyright law. The correct version of this report can be read at https://weekherald.com/2017/12/12/schwab-charles-investment-management-inc-grows-stake-in-alnylam-pharmaceuticals-inc-alny.html.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply